Crystalline Zirconium Phosphate Sorbent for Hyperkalemia Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for hyperkalemia and elevated serum toxins in patients with kidney and liver dysfunction, such as dialysis and oral sorbents like polystyrene sulfonate and zirconium cyclosilicate, are limited by low selectivity for monovalent ions, high toxicity, bowel obstruction risks, and inefficient sodium removal.
Innovation Solution
Crystalline zirconium phosphate is used as a cation exchanger to selectively remove potassium, ammonium, and sodium from the body, offering improved insolubility, binding capacity, and reduced toxicity, allowing for efficient oral administration without inducing diarrhea.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If polystyrene sulfonate (PSS) is used to adsorb potassium from the intestine, then potassium removal is achieved, but the capacity is exhausted by divalent cations (calcium and magnesium) and PSS can aggregate causing bowel obstruction
Solution Approach 1:
The patent changes the chemical parameter of the sorbent material from polystyrene sulfonate to crystalline zirconium phosphate, which fundamentally alters the adsorption mechanism. Crystalline zirconium phosphate exhibits high selectivity for monovalent cations (potassium, ammonium, sodium) over divalent cations due to its unique crystal structure and ion exchange properties, thereby achieving effective potassium removal without capacity exhaustion by calcium and magnesium. The crystalline form also prevents aggregation and bowel obstruction risks associated with PSS
Solution Approach 2:
The patent employs crystalline zirconium phosphate as a composite material with specific crystal structure that combines high cation exchange capacity with selective binding properties. This composite material structure allows simultaneous achievement of potassium removal efficiency and safety by inherently preventing the aggregation problems of PSS while maintaining high affinity for monovalent cations
2Productivity
If non-absorbable sugar (sorbitol) is administered with PSS to induce diarrhea and increase potassium removal, then potassium excretion is enhanced, but patient comfort deteriorates due to volume, sweet taste, and abdominal discomfort
Solution Approach 1:
The patent changes the mechanism parameter from inducing diarrhea via non-absorbable sugar to achieving potassium removal through selective adsorption by crystalline zirconium phosphate. This parameter change eliminates the need for sorbitol-induced diarrhea, thereby removing the associated patient discomfort, volume issues, and taste problems while maintaining effective potassium removal through the sorbent's high selectivity for monovalent cations
Solution Approach 2:
The patent extracts and eliminates the harmful component (non-absorbable sugar/sorbitol) from the treatment regimen by using crystalline zirconium phosphate as a standalone effective sorbent. This extraction removes the source of patient discomfort while preserving the therapeutic effect of potassium removal through the sorbent's inherent selective binding capability
3Quantity of substance
If dialysis is used to remove toxins from the body, then serum toxin levels are lowered, but patient quality of life deteriorates due to severe limitations on core life functions
Solution Approach 1:
The patent implements preliminary action by using crystalline zirconium phosphate sorbent to remove toxins and excess cations in the gastrointestinal tract before they are absorbed into the bloodstream. This pre-emptive removal reduces the burden on dialysis and allows for reduced dialysis frequency or intensity, thereby improving patient quality of life while maintaining effective toxin control
Solution Approach 2:
The patent introduces crystalline zirconium phosphate as an intermediary substance that facilitates toxin removal through oral administration. This intermediary acts in the gastrointestinal tract to bind and remove toxins and excess cations, providing a bridge between dietary intake and bloodstream levels, thereby reducing the need for intensive dialysis and improving patient quality of life
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Crystalline zirconium phosphate effectively lowers serum toxin levels, reduces the need for dialysis, and maintains electrolyte balance, providing a safer and more effective treatment for hyperkalemia and other toxin-related conditions.
Implementation Method 1
The crystalline zirconium phosphate can function as a cation exchanger and exchange one or more cations and adsorb cationic toxics, such as, ammonium cations, potassium cations, sodium cations, calcium cations, magnesium cations, from a patient.
Implementation Method 2
The crystalline zirconium phosphate can function as a cation exchanger and exchange one or more cations and adsorb cationic toxics
Data Source
AI summary
The present disclosure provides a crystalline zirconium phosphate and a pharmaceutical composition comprising crystalline zirconium phosphate and optionally one or more therapeutically effective agents for use in therapy. There is also provided a use of crystalline zirconium phosphate in the manufacture of a pharmaceutical composition for the treatment of a patient with abnormally high levels of one or more toxins.